Gossamer Bio, Inc. (GOSS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Gossamer Bio, Inc. (GOSS) Healthcare & Pipeline Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical firm concentrating on immunology, inflammation, and oncology. Their pipeline features GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis, positioning them in a competitive therapeutic landscape.

What Is the Investment Thesis for GOSS?

Gossamer Bio presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company’s value hinges on the successful development and commercialization of its pipeline assets, particularly GB002 for PAH, GB004 for IBD, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis. Key value drivers include positive clinical trial outcomes, regulatory approvals, and strategic partnerships. Upcoming data readouts from ongoing clinical trials represent significant catalysts. However, potential risks include clinical trial failures, regulatory setbacks, and competition from established players. With a market cap of $77.0M and a negative profit margin of -351.5%, the company's financial performance is heavily dependent on future product revenue.

Based on FMP financials and quantitative analysis

GOSS Key Highlights

Market capitalization of $77.0M reflects investor valuation of Gossamer Bio's pipeline and future potential.

• Gross margin of 99.5% indicates strong potential profitability upon successful commercialization of products.
• Negative profit margin of -351.5% highlights the significant R&D expenses typical of clinical-stage biopharmaceutical companies.
• Beta of 2.16 suggests higher volatility compared to the overall market, reflecting the speculative nature of biotech investments.
• Focus on immunology, inflammation, and oncology addresses large and growing therapeutic markets.

Who Are GOSS's Competitors?

GOSS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GOSS's Key Strengths?

Promising pipeline of drug candidates targeting significant unmet medical needs.

• Strategic partnerships with established pharmaceutical companies.
• Experienced management team with expertise in drug development and commercialization.
• Strong intellectual property portfolio protecting its drug candidates.

What Are GOSS's Weaknesses?

Clinical-stage company with no currently marketed products.

• High cash burn rate due to significant R&D expenses.
• Dependence on successful clinical trial outcomes and regulatory approvals.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive GOSS Stock Higher?

Data readouts from ongoing clinical trials for GB002 in PAH.

• Results from clinical trials for GB004 in IBD.
• Updates on the development of GB5121 for primary central nervous system lymphoma.
• Advancement of GB7208 through clinical trials for multiple sclerosis.
• Potential for new strategic partnerships and licensing agreements.

What Are the Key Risks for GOSS?

Financial-distress signal — its Altman Z-Score of -35.63 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays in the development of key drug candidates.
• Regulatory setbacks or rejection of marketing applications.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support its operations.
• Intellectual property disputes or patent challenges.

What Are the Growth Opportunities for GOSS?

• Growth opportunity 1: Successful development and commercialization of GB002 for pulmonary arterial hypertension (PAH) represents a significant growth opportunity. Positive clinical trial results and regulatory approval could position GB002 as a key player in this market. The timeline for potential commercialization depends on ongoing clinical trials and regulatory review processes.
• Growth opportunity 2: Advancing GB004, a gut-targeted oral small molecule, for the treatment of inflammatory bowel disease (IBD) offers substantial growth potential. The IBD market is expanding due to increasing prevalence and demand for targeted therapies. Successful clinical trials and subsequent regulatory approval could establish GB004 as a valuable treatment option. The timeline for commercialization is contingent on clinical trial progress and regulatory pathways.
• Growth opportunity 3: Development of GB5121, an oral Bruton's Tyrosine Kinase (BTK) inhibitor, for primary central nervous system lymphoma presents a targeted growth opportunity. The market for lymphoma treatments is expanding, and a successful BTK inhibitor could capture a significant share. Clinical trial outcomes and regulatory approvals are critical for realizing this potential. The timeline for commercialization is dependent on clinical trial results and regulatory review.
• Growth opportunity 4: Progressing GB7208, an oral BTK inhibitor, for the treatment of multiple sclerosis (MS) provides a considerable growth avenue. The MS therapeutics market is substantial, driven by the need for effective disease-modifying therapies. Positive clinical trial data and regulatory approval could position GB7208 as a competitive treatment option. The timeline for commercialization is subject to clinical trial advancements and regulatory processes.
• Growth opportunity 5: Strategic partnerships and licensing agreements can accelerate the development and commercialization of Gossamer Bio's pipeline assets. Collaborations with companies like Pulmokine, Inc. and Aerpio Pharmaceuticals, Inc. demonstrate a commitment to leveraging external expertise and resources. Expanding these partnerships could enhance the company's market reach and product portfolio. The impact of these partnerships on growth is contingent on their successful execution and the outcomes of collaborative projects.

What Opportunities Does GOSS Have?

• Expansion into new therapeutic areas and indications.
• Acquisition of additional drug candidates to broaden its pipeline.
• Out-licensing or co-development agreements with larger pharmaceutical companies.
• Accelerated regulatory pathways for its drug candidates.

What Are GOSS's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in immunology, inflammation, and oncology.
• Strategic partnerships with established pharmaceutical companies.
• Clinical trial data demonstrating efficacy and safety.

What Does GOSS Do?

Gossamer Bio, Inc., established in 2015 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing innovative therapeutics. Originally incorporated as FSG, Bio, Inc., the company rebranded to Gossamer Bio, Inc. in 2017, signaling a refined focus on addressing unmet medical needs in immunology, inflammation, and oncology. Their pipeline showcases a commitment to novel treatments, including GB002, an inhaled small molecule inhibitor targeting pulmonary arterial hypertension (PAH). GB004, a gut-targeted oral small molecule, is under development for inflammatory bowel disease (IBD). GB5121, an oral Bruton's Tyrosine Kinase (BTK) inhibitor, aims to treat primary central nervous system lymphoma. GB7208, another oral BTK inhibitor, is being developed for multiple sclerosis. These programs reflect a strategic approach to addressing significant therapeutic areas with high unmet needs. Gossamer Bio has also established strategic licensing agreements with Pulmokine, Inc. for GB002 and Aerpio Pharmaceuticals, Inc. for GB004, enhancing their development and commercialization pathways.

What Products and Services Does GOSS Offer?

• Develops therapeutics for immunology, inflammation, and oncology.
• Focuses on discovering and acquiring novel drug candidates.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals from the FDA and other health authorities.
• Commercializes approved therapeutics in the United States.
• Forms strategic partnerships and licensing agreements to enhance its pipeline.

How Does GOSS Make Money?

• Develops and patents novel therapeutic compounds.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through product sales upon regulatory approval.
• Secures funding through venture capital, public offerings, and strategic partnerships.

What Industry Does GOSS Operate In?

Gossamer Bio operates within the competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The company focuses on immunology, inflammation, and oncology, which are areas with significant unmet medical needs and substantial market opportunities. The biotechnology industry is driven by innovation and technological advancements, with companies constantly seeking to develop novel therapies. Competition comes from both large pharmaceutical companies and smaller biotech firms, all vying for market share. Success depends on factors such as clinical trial outcomes, regulatory approvals, and commercialization strategies.

Who Are GOSS's Key Customers?

• Patients suffering from pulmonary arterial hypertension (PAH).
• Patients with inflammatory bowel disease (IBD).
• Patients diagnosed with primary central nervous system lymphoma.
• Individuals affected by multiple sclerosis (MS).

Wall Street analysts project Gossamer Bio, Inc. revenue of about $38.4M for fiscal 2026, with EPS near $-0.25. The estimate reflects 5 contributing analysts.

Gossamer Bio, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.6% above estimates on average.

Gossamer Bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.63 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Gossamer Bio, Inc. stands at 174.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.20 indicates the company holds enough short-term assets to cover its near-term obligations.

Gossamer Bio, Inc. (GOSS) Valuation Context

Valued at $77.0M, GOSS is classified as a micro-cap stock. Relative to its peer group, GOSS's quantitative score of 16/100 is below the peer average of 74/100.

GOSS Revenue & Earnings Trend

In Q2 2026, GOSS generated $9.2M in top-line revenue, marking a sequential decrease of 45.5%. The company recorded net income of $16.9M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, GOSS averaged $-0.17 in diluted EPS.

Company Profile

Gossamer Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Faheem Hasnain. GOSS has traded publicly since 2019.

GOSS Financials

GOSS Latest News

GOSS Analyst Consensus

GOSS MoonshotScore

Latest Gossamer Bio, Inc. Analysis

Common Questions About GOSS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources